Awaiting regulatory approvals to launch Covaxin for children: Bharat Biotech

"This represents one of the first approvals worldwide for COVID-19 vaccines for the 2-18 age group. Bharat Biotech sincerely thanks the DCGI, Subject Experts Committee, and CDSCO for their expedited review process. We now await further regulatory approvals from the CDSCO prior to product launch and market availability of Covaxin for children," Bharat Biotech said in a statement.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news